Welcome to our dedicated page for Tvardi Therapeutics news (Ticker: TVRD), a resource for investors and traders seeking the latest updates and insights on Tvardi Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tvardi Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tvardi Therapeutics's position in the market.
Tvardi Therapeutics (NASDAQ: TVRD) announced its upcoming presentation at the American Thoracic Society 2025 Annual Conference in San Francisco. The presentation will highlight research on their STAT3 inhibitor, TTI-101, for treating idiopathic pulmonary fibrosis (IPF). Key findings show that ~60% of IPF-associated dysregulated genes are not addressed by current approved therapies (nintedanib and pirfenidone), termed the "IPF therapeutic gap." Research using single-cell RNA sequencing identified STAT3 as a dominant regulatory transcription factor in IPF. Notably, TTI-101 showed greater repression of genes within alveolar fibroblasts compared to existing treatments and demonstrated ability to downregulate genes involved in extracellular matrix production, including collagen genes.
FAQ
What is the current stock price of Tvardi Therapeutics (TVRD)?
What is the market cap of Tvardi Therapeutics (TVRD)?
